Literature DB >> 16019946

Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.

K W Ward1, R Nagilla, L J Jolivette.   

Abstract

The prediction of human pharmacokinetics is often based on in vivo preclinical pharmacokinetic data. However, to date, no clear guidance has been available about the relative ability of the major preclinical species to estimate human oral exposure. The study was conducted to survey the literature on oral pharmacokinetic parameters in rat, dog, monkey and human, and to compare various methods for prediction of oral exposure in humans. Fifty-six non-peptide xenobiotics were identified with oral pharmacokinetic data in rat, dog, monkey and human, and comparison of the data from each species to humans was conducted along with an evaluation of the molecular features of these compounds. Monkey liver blood flow-based oral exposure was qualitatively and quantitatively more predictive of human oral exposure than rat or dog. Furthermore, generation of data in three versus two preclinical species did not always improve human predictivity. The use of molecular properties did not substantially improve the prediction of human oral exposure compared with the prediction from monkey alone. These observations confirm the continued importance of non-human primates in preclinical pharmacokinetics, and also have implications for pharmacokinetic lead optimization and for prediction of human pharmacokinetic parameters from in vivo preclinical data.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16019946     DOI: 10.1080/00498250400028197

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

Review 1.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

2.  Projection of exposure and efficacious dose prior to first-in-human studies: how successful have we been?

Authors:  Christine Huang; Ming Zheng; Zheng Yang; A David Rodrigues; Punit Marathe
Journal:  Pharm Res       Date:  2007-09-25       Impact factor: 4.200

3.  Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat.

Authors:  T Nishimura; Y Kato; N Amano; M Ono; Y Kubo; Y Kimura; H Fujita; A Tsuji
Journal:  Pharm Res       Date:  2008-07-15       Impact factor: 4.200

4.  Behavioral pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys.

Authors:  Gail Pereira Do Carmo; Robin Polt; Edward J Bilsky; Kenner C Rice; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2008-05-29       Impact factor: 4.030

Review 5.  Pain assessment in animal models: do we need further studies?

Authors:  Carmelo Gigliuto; Manuela De Gregori; Valentina Malafoglia; William Raffaeli; Christian Compagnone; Livia Visai; Paola Petrini; Maria Antonietta Avanzini; Carolina Muscoli; Jacopo Viganò; Francesco Calabrese; Tommaso Dominioni; Massimo Allegri; Lorenzo Cobianchi
Journal:  J Pain Res       Date:  2014-05-08       Impact factor: 3.133

6.  The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data.

Authors:  Andrés Olivares-Morales; Oliver J D Hatley; David Turner; Aleksandra Galetin; Leon Aarons; Amin Rostami-Hodjegan
Journal:  Pharm Res       Date:  2013-09-27       Impact factor: 4.200

Review 7.  Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.

Authors:  Sheila Annie Peters; Christopher R Jones; Anna-Lena Ungell; Oliver J D Hatley
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.